Drug manufacturer, Teva Pharmaceutical Industries Ltd. Has planned to appeal a $356 million Las Vegas constituency court ruling that was awarded to an applicant, who is of the opinion that he contracted hepatitis C, when one of Teva's drug vials had been used by over one patient.

Adjudicators in Las Vegas forwarded order to Teva and Baxter Healthcare Corp. to reimburse a collective $500 million in penalizing damages in the first of almost 250 civil cases that stemmed from a hepatitis C epidemic interrelated to its drug propofol two years back.

Teva thinks that the proof clearly illustrates that if the applicant contracted hepatitis as he has alleged, it was due to a correctly labeled product being used wrongly at the clinic under debate.
It also believes that there are numerous reasons for appeal, and therefore intends to compete the ruling with all its energy.

The drug maker and distributor were capable of providing proof that the propofol had been used by endoscopy clinics at the heart of the hepatitis C outburst. No less than nine and probably as many as 114 patients were infected with the illness.

The Southern Nevada Health District recommended almost 50,000 patients, who received endoscopy procedures at the clinics, to get themselves tested.